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Background
Contrast-enhanced cardiovascular magnetic resonance
(CMR) with late gadolinium enhancement (LGE) has
emerged as an in vivo marker of myocardial fibrosis,
although its significance in identifying high risk hyper-
trophic cardiomyopathy (HCM) patients remains unre-
solved. Previous meta-analyses have included studies
with data involving overlapping patient populations,
thus confounding effect estimates.
Methods
We searched PubMed and Web of Science for clinical trials
that investigated the prognostic utility of LGE in HCM
patients. We excluded studies with overlapping data.
Pooled odds ratios (ORs), hazard ratios (HRs) and 95%
confidence intervals (CIs) were calculated to assess the role
of LGE CMR in the risk stratification of HCM patients.
Results
Five studies of unique cohorts were retrieved from 393
citations for the analysis. In total, 2993 patients (mean age
= 54.6 years; median follow up = 36.8 months) were
included. After synthesizing data, meta-analysis showed
that the presence of LGE was associated with a signifi-
cantly increased risk of sudden cardiac death (SCD)/
aborted SCD (pooled OR = 3.42, 95%CI = 1.97-5.94; P <
0.001), cardiac death (pooled OR = 2.93, 95%CI = 1.53-
5.61; P = 0.001), all-cause mortality (pooled OR=1.80, 95%
CI = 1.21-2.69; P = 0.004), and a trend towards increased
risk of heart failure death (pooled OR = 2.21, 95%CI =
0.84-5.80; P = 0.107). Three publications reported results
with quantitative LGE. There was a significant relationship
between the extent of LGE and risk of SCD (pooled HR
1.56/10% LGE, 95% CI = 1.33-1.82, p < 0.0001), all-cause
mortality (pooled HR 1.29/10%LGE, 95% CI = 1.09-1.51,
p = 0.002), heart failure mortality (pooled HR 1.61/10%
LGE, 95% CI 1.21-2.13, p = 0.001), and cardiovascular
mortality (pooled HR 1.57/10% LGE, 95% CI 1.30-1.89,
p < 0.001). After adjusting for baseline characteristics, the
extent of LGE remained a strong independent predictor
for SCD events (pooled HRadjusted 1.36/10%LGE, 95% CI
1.10-1.69, p = 0.005).
Conclusions
Extensive LGE by CMR identifies high-risk HCM patients,
and is an independent predictor of sudden death. Quanti-
tative assessment of myocardial fibrosis by LGE can thus
be a clinically useful tool to help risk stratify patients with
HCM.
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Figure 1 Forest plot of presence of LGE and risk of adverse events.
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